IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-154099 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Immune-mediated Inflammatory Disease (IMID) Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET
7.1 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA IMMUNE-MEDIATED INFLAMMATORY DISEASE (IMID) TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 GlaxoSmithKline
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Eli Lilly and Company
16.3 AstraZeneca
16.4 Bristol-Myers
16.5 Sanofi SA
16.6 Roche
16.7 Enlivex Therapeutics Ltd.
16.8 Immune Pharmaceuticals
16.9 Tanabe Pharma Corporation
16.10 Abbreviation
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Treatment TypeTraditional Drugs
   o Corticosteroids
   o Non-steroidal Anti-inflammatory Drugs
   o Anti-TNF Agents
   o Others
Targeted Biologic Therapies
Novel Therapies
By Indication
Asthma
Chronic Obstructive Pulmonary Diseases (COPD)
Inflammatory Bowel Disease (IBD)
Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis (RA)
Psoriasis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Companies
GlaxoSmithKline
Eli Lilly and Company
AstraZeneca
Bristol-Myers
Sanofi SA
Roche
Enlivex Therapeutics Ltd.
Immune Pharmaceuticals
Tanabe Pharma Corporation
Abbreviation
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.